Stratify stroke patients into 3 risk group according to levels of copeptin and NT-proBNP: low risk (both biomarkers below average), those with intermediate risk (with one of the two biomarkers above average) and those at increased risk (both markers above average). This evidence concerns the gene AVP and stroke disorder.